Ondansetron

Belonging to the Syrups category within the Anti-Emetic and Pediatric Care therapeutic segments, Ondansetron Oral Syrup is a selective serotonin 5-HT3 receptor antagonist — one of the most clinically significant antiemetic drug classes developed in the past four decades. Its liquid formulation at 2mg per 5ml makes it the preferred dosage form for pediatric oncology patients, post-operative care settings, and adult outpatients unable to swallow tablets during episodes of nausea.

Ondansetron belongs to the same pharmacological class as Granisetron and Palonosetron, but is the most widely prescribed 5-HT3 antagonist in Indian oncology and general medicine practice due to its established clinical record, broad indication profile, and favorable cost-to-efficacy ratio. The oral liquid formulation provides bioavailability of approximately 60% (due to hepatic first-pass metabolism), with peak plasma concentrations achieved within 1–2 hours of administration.

For pharmaceutical marketing companies, Ondansetron Syrup is a specialty prescription product with institutional hospital, oncology center, and pharmacy channel demand — a consistent, high-repeat-prescription segment with strong brand differentiation opportunities through premium dropper pack presentation. Saar Biotech manufactures this formulation from our facility in Baddi, Himachal Pradesh.

At Saar Biotech, we manufacture Ondansetron Hydrochloride Syrup using a precision-formulated oral solution process that resolves the two primary challenges of this product — the intensely bitter taste of the Ondansetron API and the need for exact label-claim accuracy at the 2mg per 5ml concentration.

• Advanced Bitter Taste Masking: Raw Ondansetron Hydrochloride is one of the most bitter APIs in common pharmaceutical use. Our R&D team employs a multi-layer sweetening and flavoring system — combining a sweetener base, flavor masking agents, and a premium fruit or strawberry flavor profile — to deliver a finished syrup that nauseated patients can actually accept willingly, which is the defining commercial requirement for an antiemetic oral liquid.
• Precise Low-Concentration Assay Control: At 2mg per 5ml, Ondansetron is a low-dose API where even minor formulation or filling deviations represent clinically meaningful percentage errors. Our HPLC-validated batch release protocol confirms exact concentration at 98–102% of label claim for every batch.
• Dropper Pack Precision: The 30ml dropper format requires a calibrated dropper assembly that delivers accurate per-squeeze volumes for pediatric weight-based dosing. Our dropper systems are verified against the specific viscosity of the Ondansetron syrup base.
• Premium Dropper Pack Presentation: Drip-off Brand Name Embossed mono-cartons, sticker labels with printed caps, and high-quality dropper assemblies give Ondansetron brands a clinically professional appearance appropriate for oncology and institutional supply channels.

Ondansetron HCl 2mg/5ml Syrup is manufactured and supplied by Saar Biotech for the following DCGI-approved clinical indications:

• Chemotherapy-Induced Nausea and Vomiting (CINV): Prevention of nausea and vomiting associated with highly emetogenic agents (cisplatin ≥50mg/m²) and moderately emetogenic chemotherapy regimens — the primary indication driving institutional formulary demand.
• Radiation-Induced Nausea and Vomiting (RINV): Prevention in patients receiving total body irradiation, single high-dose abdominal fractions, or daily fractionated abdominal radiation.
• Postoperative Nausea and Vomiting (PONV): Prevention and treatment following surgical procedures where PONV risk is elevated — particularly in high-risk patients (female, non-smokers, history of PONV, opioid analgesia).
• Pediatric Antiemetic Therapy: The 2mg/5ml liquid formulation enables accurate weight-based antiemetic dosing in children from 6 months of age, covering pediatric oncology and surgical recovery settings.

This is a Schedule H prescription drug requiring a valid medical prescription for dispensing.

Clinical Mechanism — Selective 5-HT3 Antagonism

The primary mechanism driving chemotherapy- and radiation-induced vomiting is serotonin-mediated. Cytotoxic agents damage the gastrointestinal mucosa, triggering enterochromaffin cells to release large quantities of serotonin (5-HT) into the gut lumen and portal circulation. This serotonin activates 5-HT3 receptors located on vagal afferent nerve terminals in the gut wall, sending emetic signals to the dorsal vagal complex (vomiting center) in the brainstem, and to the chemoreceptor trigger zone (CTZ) in the area postrema.

Ondansetron competitively and selectively blocks these 5-HT3 receptors at both peripheral (gut vagal) and central (CTZ) locations, interrupting the primary serotonergic emetic pathway. Because 5-HT3 antagonism does not affect dopamine receptors (unlike metoclopramide), Ondansetron carries no risk of extrapyramidal side effects — a major clinical and commercial advantage in pediatric settings.

Manufacturing Integrity

• Chemical Stability of Ondansetron HCl in Liquid: Ondansetron Hydrochloride is subject to hydrolytic degradation in aqueous formulations, particularly at non-optimal pH levels. Our syrup vehicle is pH-buffered within the validated stability window that maximizes Ondansetron’s aqueous stability, ensuring full label-claim potency is maintained from the manufacturing date to the 24-month expiry.
• Preservative System: The multi-dose 30ml bottle is opened and reclosed multiple times during the treatment course. Our validated preservative system maintains microbiological integrity across this repeated-use pattern, meeting IP antimicrobial preservative efficacy requirements.

• Predictable Oral Bioavailability: Oral Ondansetron achieves approximately 60% bioavailability due to hepatic first-pass metabolism, with peak plasma concentration reached in 1–2 hours. This predictable absorption profile means the standard 2mg/5ml dose reliably delivers therapeutic plasma levels within the clinical timeframe needed for chemotherapy premedication.
• Protein Binding and Tissue Distribution: Ondansetron is 70–76% bound to plasma proteins and distributes into erythrocytes, providing a consistent, well-characterized pharmacokinetic profile across patient populations. The mean elimination half-life in adults is approximately 4 hours, supporting the established dosing frequency of every 4–8 hours depending on the emetogenic risk of the treatment protocol.
• Dropper Format = Institutional and Pediatric Prescription Driver: The 30ml dropper pack is the dominant commercial format for Ondansetron Syrup in India because it serves both pediatric dosing (where the dropper enables precise weight-based dose measurement) and adult outpatient use (where a compact 30ml supply covers a typical chemotherapy day treatment course). This format specificity creates a commercially distinct SKU separate from tablet presentations.
• Repeat Prescription Pattern: Chemotherapy patients typically receive multiple treatment cycles, and Ondansetron is prescribed for every cycle. This creates a predictable, repeat-prescription revenue pattern for brands well-positioned in oncology center formularies — a high-value institutional channel that Saar Biotech’s manufacturing quality and documentation standards support.

Saar Biotech provides specialized Contract Manufacturing (CMO) and Third-Party Manufacturing for Ondansetron HCl 2mg/5ml Oral Syrup from our oral liquid manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Dedicated oral liquid filling lines with automated 30ml filling and dropper assembly, inline fill-volume checks, and secondary packaging for mono-carton insertion.
• Capacity: Pilot batches from 5,000 units; commercial scale to 2,00,000+ units per production run; 200×30ml shipper configurations for institutional bulk supply.
• Quality Lab: In-house GLP-certified lab with HPLC for Ondansetron assay at 2mg/5ml, pH and specific gravity testing, MLT, dropper calibration verification, and fill volume accuracy.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 30ml and 60ml amber PET bottles with calibrated dropper; Drip-off Brand Name Embossed carton, sticker label, normal label, printed cap, plain cap; with/without carton options.
• Regulatory: Schedule H compliant. Full COA, batch manufacturing records provided.
• MOQ: 5,000–10,000 units per SKU.

1. Store Below 30°C: The syrup base must be kept below 30°C in a cool, dry place. Elevated temperatures accelerate Ondansetron hydrolytic degradation and can alter the taste-masking system’s efficacy — affecting patient acceptance over the shelf life.
2. Light Protection: Ondansetron is sensitive to prolonged UV exposure. The amber PET bottle provides primary protection; the outer carton provides secondary protection during distribution and pharmacy display. Patients should be advised to keep the bottle in its carton until the syrup is needed.
3. Dropper Hygiene: The dropper tip should not contact the patient’s mouth or tongue to prevent microbial contamination of the 30ml bottle during the multi-day treatment course. Wipe the dropper tip clean after each use and replace the cap securely.
4. In-Use Period: Once opened, the 30ml bottle should be used within the treatment course duration as specified by the prescriber. The preservative system maintains microbiological safety for the normal in-use period of a chemotherapy or radiation therapy course.

Every batch of Ondansetron HCl 2mg/5ml Syrup is quarantined until it passes a complete analytical release protocol in our GLP-certified QC laboratories in Baddi:

• HPLC Assay (Label Claim Accuracy): Validated HPLC quantification of Ondansetron Hydrochloride confirmed at 2mg per 5ml (98–102% of IP label claim) — the most critical release test for this low-concentration antiemetic syrup.
• pH Testing: Verified within the buffered stability range that maintains Ondansetron chemical integrity and ensures patient comfort.
• Specific Gravity: Confirms syrup base density is consistent with specifications for accurate dosing from calibrated dropper.
• Microbial Limit Testing (MLT): IP-mandated testing confirming absence of specified pathogens — essential for a multi-dose product used in immunocompromised oncology patients.
• Dropper Calibration: The dropper assembly is verified to deliver the labeled dose volume within accepted tolerance against the finished product’s viscosity.
• Fill Volume Accuracy: Automated and manual checks confirm each 30ml and 60ml bottle is filled within specification.
• Certificate of Analysis (COA): Issued with every B2B consignment for partner documentation and institutional formulary records.

Ondansetron Syrup is generally well tolerated. Common adverse effects include headache (the most frequent, reported in approximately 9% of patients), constipation, lightheadedness, dizziness, drowsiness, and mild fatigue. Constipation is particularly notable in post-operative settings where reduced mobility and opioid analgesia co-contribute.

Critical safety considerations: QT interval prolongation occurs in a dose-dependent manner — patients with congenital long QT syndrome, uncorrected electrolyte abnormalities, or co-administration of other QT-prolonging drugs require ECG monitoring. Ondansetron is contraindicated with apomorphine. Abdominal surgery patients should be monitored for signs of progressive ileus, as Ondansetron may mask gut motility changes. Pregnancy use should be carefully evaluated by the prescribing physician.

For B2B manufacturing enquiries, third-party contracts, or to request pricing and packaging options for Ondansetron HCl 2mg Oral Syrup, please use the enquiry form below.